Amantadine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Amantadine: From Parkinson’s Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Amantadine is a well-established agent used for Parkinson’s disease and influenza A, acting primarily through non-competitive NMDA receptor antagonism and dopaminergic enhancement. The TxGNN model predicts it may be effective for Rasmussen Subacute Encephalitis, a rare, chronic autoimmune encephalitis causing progressive unilateral brain destruction. Currently, no clinical trials and no publications specifically support this repurposing direction — the prediction rests entirely on model inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s disease; influenza A (not currently marketed in India) |
| Predicted New Indication | Rasmussen Subacute Encephalitis |
| TxGNN Prediction Score | 99.48% |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the regulatory data on record. Based on known pharmacological information, Amantadine functions as a non-competitive NMDA receptor antagonist (blocking glutamate-mediated excitotoxicity) and a dopaminergic agent (promoting dopamine release and inhibiting reuptake). These dual mechanisms underlie its established use in Parkinson’s disease, where it reduces motor symptoms and drug-induced dyskinesia.
Rasmussen Encephalitis (RE) is a rare, progressive autoimmune condition characterised by T-cell-mediated unilateral hemispheric inflammation and neuronal destruction. While the primary pathology is immune-driven, secondary glutamate excitotoxicity via NMDA receptor over-activation contributes to neuronal death and propagation of seizure activity. A subset of RE patients also carry antibodies against GluR3 (an AMPA receptor subunit), suggesting cross-talk with glutamate receptor pathways. Amantadine’s NMDA antagonism theoretically could reduce this secondary excitotoxic cascade — analogous to the rationale supporting Memantine use in neuroinflammatory conditions.
However, the mechanistic link is indirect and weak. RE’s core pathophysiology is autoimmune, not dopaminergic or glutamatergic in origin. Amantadine does not address the T-cell-mediated inflammation that drives the disease. The TxGNN high score likely reflects broad network connectivity between “antiviral/antiparkinson” drug nodes and “encephalitis/CNS inflammation” disease nodes in the knowledge graph, rather than a specific mechanistic fit. This should be treated as a hypothesis-generating signal, not a clinically actionable finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Amantadine currently has no registered products in India. There are no active licenses, approved dosage forms, or approved indications on record.
Safety Considerations
Formal package insert warnings and contraindications data are not available in this evidence pack. Please refer to the original package insert for complete safety information.
Key Drug Interactions (93 interactions on record; selected below by clinical significance):
| Interacting Drug | Severity | Clinical Note |
|---|---|---|
| Bupropion | Major | Increased risk of seizures and CNS toxicity; concurrent use generally contraindicated |
| Atropine | Moderate | Additive anticholinergic effects; risk of urinary retention, confusion, dry mouth |
| Scopolamine | Moderate | Additive anticholinergic effects |
| Hyoscyamine | Moderate | Additive anticholinergic effects |
| Glycopyrronium | Moderate | Additive anticholinergic effects |
| Dicyclomine | Moderate | Additive anticholinergic effects |
| Trospium | Moderate | Additive anticholinergic effects |
| Methscopolamine | Moderate | Additive anticholinergic effects |
| Mepenzolate | Moderate | Additive anticholinergic effects |
| Propantheline | Moderate | Additive anticholinergic effects |
| Clidinium | Moderate | Additive anticholinergic effects |
| Metoclopramide | Moderate | Pharmacodynamic antagonism; amantadine may reduce metoclopramide efficacy |
| Polyethylene glycol 3350 | Moderate | Altered GI transit may affect amantadine absorption |
| Picosulfuric acid | Moderate | Altered GI transit may affect amantadine absorption |
| Sodium sulfate | Moderate | Altered GI transit may affect amantadine absorption |
⚠️ The full interaction list contains 93 entries. The anticholinergic burden is a particularly notable concern for elderly or neurologically impaired patients. Verify all concurrent medications before any clinical trial design.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model assigns a high confidence score (99.48%), but this reflects network topology in the knowledge graph rather than disease-specific mechanistic evidence. Rasmussen Encephalitis is a rare autoimmune CNS disease whose primary pathology — T-cell-mediated neuroinflammation — is not directly addressed by Amantadine’s known mechanisms. There are zero supporting clinical trials and zero supporting publications. This is a model-only prediction (L5) with weak-to-moderate indirect mechanistic plausibility.
To proceed to the next stage, the following is needed:
- MOA confirmation: Retrieve full Amantadine DrugBank entry including mechanism, pharmacodynamics, and pharmacokinetics
- Preclinical evidence search: Broaden literature review to include NMDA antagonism in autoimmune encephalitis animal models
- RE patient population context: Confirm whether any RE sub-types (anti-GluR3+) might be selectively responsive to glutamate pathway modulation
- Comparator analysis: Review Memantine (structurally and mechanistically similar NMDA antagonist) for any RE-related case reports or small series
- Safety profile completion: Obtain TFDA/FDA/EMA package insert to document formal contraindications and warnings, particularly regarding CNS adverse effects (confusion, hallucinations, seizures) relevant to encephalitis patients
- Orphan drug pathway assessment: Given RE’s ultra-rare status, evaluate eligibility for orphan drug designation in India, which may lower the evidence threshold for exploratory IND
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.